13 result(s) for 'ACD'
1 - 10 of 13 results for 'ACD'
Sort by
Show
Incorporation and Automation of RNAscope Technology into your COVID-19 Viral Pathogenesis Research. Research Use Only, Not for Clinical Diagnostic Procedure
For Research Use Only. Not For Diagnostic Use. Incorporation of the highly sensitive and specific RNAscope technology into your COVID-19 Viral Pathogenesis Research Jyoti Sheldon Applications Research Use Only, Not for Clinical Diagnostic Procedure
Agenda RNAscope technology overview COVID-19 Offerings COVID-19 Publications Research Use Only, Not for Clinical Diagnostic Procedure
RNAscope®In Situ Hybridization (ISH) Technology A hybridization-based signal amplification system with a unique probe design - Simultaneous signal amplification and background suppression Amplification Target-specific binding A specific and sensit...
This detection system is for in vitro diagnostic use.The BOND RNAscope® Brown Detection enables the user to perform chromogenic in situ hybridization (CISH) with Advanced Cell Diagnostics (ACD) proprietary RNA ISH probes. Performance claims for compatible probes have not been established. Probes used in conjunction with BOND RNAscope® Brown Detection should be validated by the user in accordance with local laws and regulations. The BOND RNAscope®...
Research-use-only RNA-ISH probes now available for COVID-19 on our automated platform
Leica Biosystems, in partnership with Bio-Techne Corporation, announces the automation of RNAscope™ COVID-19 probes’ on BOND RX*, its staining platform, for research use only. Researchers now have the capability to automate their COVID-19 research protocols, reducing manual labor and turnaround time.
“We expect the automation of COVID-19 research protocols on BOND RX to enable researchers to achieve breakthroughs faster in their research for vaccines, treatment or other vital areas of investigation,” said Melissa Aquino, President, Leica Biosystems. “The partnership with Bio-Techne has enabled us to offer RNAscope COVID-19 probes to our BOND RX customers, which is an example of our commitment ...
Son Bui is a Senior Field Application Scientist at Bio-techne. Son has over twenty years’ experience in the life science industry, contributing to the successful launch of fourteen commercial products. Son began his career at GE/Amersham (formerly Molecular Dynamics) and was a key contributor to the development and launch of the Cancer gene chip. In his next position at Panomics, Son’s achievements included co-developing and launching six commercial QuantiGene, QuantiGene Plex, and ViewRNA product lines. Next at ACD, Son was one of the first five senior scientists that developed the RNAscope assays from scratch. During the first six years at ACD, Son contributed to the development and launch of five products. Son has co-published fourteen peer-reviewed articles and earned a B.S...
Jennifer Stover has been with Advanced Cell Diagnostics for over 3 years and manages the ACD Field Applications Team. Prior to coming to ACD, she has worked as an FAS supporting Next Gen Sequencing and microarray technologies and started her career at Wyeth Pharma performing some of earliest clinical pharmacogenomics studies on GeneChip microarrays with the goal of developing gene expression profiles signatures of drug response. Jen lives north of Boston and spends most of her days in the Tech Square area working to support area RNAscope users.
Blake McAlpin is a Field Application Scientist in the Boston area for ACD. He received his Ph.D. in Neuroscience from MD Anderson UTHealth Graduate School of Biomedical Sciences in 2021 where he studied neurotoxic side effects of chemotherapy treatment with a focus on microglia-mediated mechanisms underlying cognitive dysfunction. His master’s degree from Université Denis Diderot (Paris VII) focused on endocrine disruption by BPA with regard to the endogenous circadian clock. He received his bachelor's degree in Neuroscience from the University of Michigan.